Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Miravant reports promising interim phase III results for breast cancer trial

Dec. 4, 1997

Pfizer discontinues collaboration with Megabios

Dec. 3, 1997

VEGF receptor tyrosine kinase inhibitors under development at Zeneca

Dec. 3, 1997

Water-soluble taxanes reported in patent literature

Dec. 3, 1997

EntreMed reports positive preclinical results using Endostatin

Dec. 3, 1997

ALVAC-IL-12 gene therapy effective in murine model of breast cancer

Dec. 2, 1997

Heterocyclic antitumor agents from Dainippon

Dec. 2, 1997

Steroidal anticancer compounds isolated from C. africana

Dec. 2, 1997

Angiostatin production mechanism elucidated; may permit large-scale studies

Dec. 2, 1997

U.S. patent covers new melanoma antigen/MAb discovered by Cytoclonal

Dec. 1, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...